Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumors.

Lindquist KJ, Sanford T, Friedlander TW, Paris PL, Porten SP.

PLoS One. 2017 Nov 15;12(11):e0187975. doi: 10.1371/journal.pone.0187975. eCollection 2017.

2.

Validation of GEMCaP as a DNA Based Biomarker to Predict Prostate Cancer Recurrence after Radical Prostatectomy.

Nguyen HG, Welty C, Lindquist K, Ngo V, Gilbert E, Bengtsson H, Magi-Galluzzi C, Jean-Gilles J, Yao J, Cooperberg M, Messing E, Klein EA, Carroll PR, Paris PL.

J Urol. 2017 Sep 20. pii: S0022-5347(17)77554-4. doi: 10.1016/j.juro.2017.09.071. [Epub ahead of print]

PMID:
28941923
3.

High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.

Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ.

Clin Genitourin Cancer. 2017 Dec;15(6):733-741.e1. doi: 10.1016/j.clgc.2017.05.026. Epub 2017 Jun 3.

PMID:
28655452
4.

Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.

Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ.

Mol Cancer Res. 2017 Sep;15(9):1221-1229. doi: 10.1158/1541-7786.MCR-17-0196. Epub 2017 Jun 7.

PMID:
28592703
5.

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.

Anantharaman A, Friedlander T, Lu D, Krupa R, Premasekharan G, Hough J, Edwards M, Paz R, Lindquist K, Graf R, Jendrisak A, Louw J, Dugan L, Baird S, Wang Y, Dittamore R, Paris PL.

BMC Cancer. 2016 Sep 22;16(1):744.

6.

An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer.

Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona TG, Collisson EA, Friedlander TW, Paris PL.

Cancer Lett. 2016 Sep 28;380(1):144-52. doi: 10.1016/j.canlet.2016.06.017. Epub 2016 Jun 22.

PMID:
27343980
7.

Mutational Landscape of Aggressive Prostate Tumors in African American Men.

Lindquist KJ, Paris PL, Hoffmann TJ, Cardin NJ, Kazma R, Mefford JA, Simko JP, Ngo V, Chen Y, Levin AM, Chitale D, Helfand BT, Catalona WJ, Rybicki BA, Witte JS.

Cancer Res. 2016 Apr 1;76(7):1860-8. doi: 10.1158/0008-5472.CAN-15-1787. Epub 2016 Feb 26.

8.

Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer.

Nordström T, Van Blarigan EL, Ngo V, Roy R, Weinberg V, Song X, Simko J, Carroll PR, Chan JM, Paris PL.

Prostate. 2016 Mar;76(4):339-48. doi: 10.1002/pros.23125. Epub 2015 Nov 20.

9.

Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma.

Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, Fang D, Huang X, Tom MW, Ngo V, Solomon D, Mueller S, Paris PL, Zhang Z, Petritsch C, Gupta N, Waldman TA, James CD.

Nat Med. 2014 Dec;20(12):1394-6. doi: 10.1038/nm.3716. Epub 2014 Nov 17.

10.

Next generation sequencing of pancreatic cyst fluid microRNAs from low grade-benign and high grade-invasive lesions.

Wang J, Paris PL, Chen J, Ngo V, Yao H, Frazier ML, Killary AM, Liu CG, Liang H, Mathy C, Bondada S, Kirkwood K, Sen S.

Cancer Lett. 2015 Jan 28;356(2 Pt B):404-9. doi: 10.1016/j.canlet.2014.09.029. Epub 2014 Oct 7.

PMID:
25304377
11.

Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis.

Heselmeyer-Haddad KM, Berroa Garcia LY, Bradley A, Hernandez L, Hu Y, Habermann JK, Dumke C, Thorns C, Perner S, Pestova E, Burke C, Chowdhury SA, Schwartz R, Schäffer AA, Paris PL, Ried T.

Am J Pathol. 2014 Oct;184(10):2671-86. doi: 10.1016/j.ajpath.2014.06.030. Epub 2014 Aug 14.

12.

Performance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) tumor biomarker for identifying recurrent disease in African American patients.

Levin AM, Lindquist KJ, Avila A, Witte JS, Paris PL, Rybicki BA.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1677-82. doi: 10.1158/1055-9965.EPI-13-1124. Epub 2014 Jun 2.

13.

Recurrent epimutations activate gene body promoters in primary glioblastoma.

Nagarajan RP, Zhang B, Bell RJ, Johnson BE, Olshen AB, Sundaram V, Li D, Graham AE, Diaz A, Fouse SD, Smirnov I, Song J, Paris PL, Wang T, Costello JF.

Genome Res. 2014 May;24(5):761-74. doi: 10.1101/gr.164707.113. Epub 2014 Apr 7.

14.

Looking back, to the future of circulating tumor cells.

Friedlander TW, Premasekharan G, Paris PL.

Pharmacol Ther. 2014 Jun;142(3):271-80. doi: 10.1016/j.pharmthera.2013.12.011. Epub 2013 Dec 19. Review.

PMID:
24362084
15.

Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.

Friedlander TW, Ngo VT, Dong H, Premasekharan G, Weinberg V, Doty S, Zhao Q, Gilbert EG, Ryan CJ, Chen WT, Paris PL.

Int J Cancer. 2014 May 15;134(10):2284-93. doi: 10.1002/ijc.28561. Epub 2014 Jan 2.

16.

Common structural and epigenetic changes in the genome of castration-resistant prostate cancer.

Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, Azameera A, Rubin MA, Pienta KJ, Chinnaiyan A, Ittmann MM, Ryan CJ, Paris PL.

Cancer Res. 2012 Feb 1;72(3):616-25. doi: 10.1158/0008-5472.CAN-11-2079. Epub 2011 Dec 7.

17.

Detection of recurrent rearrangement breakpoints from copy number data.

Ritz A, Paris PL, Ittmann MM, Collins C, Raphael BJ.

BMC Bioinformatics. 2011 Apr 21;12:114. doi: 10.1186/1471-2105-12-114.

18.

A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer.

Paris PL, Weinberg V, Albo G, Roy R, Burke C, Simko J, Carroll P, Collins C.

Clin Cancer Res. 2010 Jan 1;16(1):195-202. doi: 10.1158/1078-0432.CCR-09-0948. Epub 2009 Dec 22.

19.
20.

Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer.

Paris PL, Kobayashi Y, Zhao Q, Zeng W, Sridharan S, Fan T, Adler HL, Yera ER, Zarrabi MH, Zucker S, Simko J, Chen WT, Rosenberg J.

Cancer Lett. 2009 May 18;277(2):164-73. doi: 10.1016/j.canlet.2008.12.007. Epub 2009 Jan 21.

PMID:
19162393
21.

An oncogenic role for the multiple endocrine neoplasia type 1 gene in prostate cancer.

Paris PL, Sridharan S, Hittelman AB, Kobayashi Y, Perner S, Huang G, Simko J, Carroll P, Rubin MA, Collins C.

Prostate Cancer Prostatic Dis. 2009;12(2):184-91. doi: 10.1038/pcan.2008.45. Epub 2008 Sep 9.

22.

Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.

Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G, Shah RB, Loda M, Rubin MA.

Clin Cancer Res. 2008 Jun 1;14(11):3380-5. doi: 10.1158/1078-0432.CCR-07-5194.

23.

A sequence-based survey of the complex structural organization of tumor genomes.

Raphael BJ, Volik S, Yu P, Wu C, Huang G, Linardopoulou EV, Trask BJ, Waldman F, Costello J, Pienta KJ, Mills GB, Bajsarowicz K, Kobayashi Y, Sridharan S, Paris PL, Tao Q, Aerni SJ, Brown RP, Bashir A, Gray JW, Cheng JF, de Jong P, Nefedov M, Ried T, Padilla-Nash HM, Collins CC.

Genome Biol. 2008;9(3):R59. doi: 10.1186/gb-2008-9-3-r59. Epub 2008 Mar 25.

24.

Evaluation of whole genome amplification protocols for array and oligonucleotide CGH.

Hittelman A, Sridharan S, Roy R, Fridlyand J, Loda M, Collins C, Paris PL.

Diagn Mol Pathol. 2007 Dec;16(4):198-206.

PMID:
18043282
25.

High resolution oligonucleotide CGH using DNA from archived prostate tissue.

Paris PL, Sridharan S, Scheffer A, Tsalenko A, Bruhn L, Collins C.

Prostate. 2007 Sep 15;67(13):1447-55.

26.

TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.

Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA.

Am J Surg Pathol. 2007 Jun;31(6):882-8.

PMID:
17527075
27.

Morphological features of TMPRSS2-ERG gene fusion prostate cancer.

Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA.

J Pathol. 2007 May;212(1):91-101.

28.

Genomic profiling of hormone-naïve lymph node metastases in patients with prostate cancer.

Paris PL, Hofer MD, Albo G, Kuefer R, Gschwend JE, Hautmann RE, Fridyland J, Simko J, Carroll PR, Rubin MA, Collins C.

Neoplasia. 2006 Dec;8(12):1083-9.

29.

Decoding the fine-scale structure of a breast cancer genome and transcriptome.

Volik S, Raphael BJ, Huang G, Stratton MR, Bignel G, Murnane J, Brebner JH, Bajsarowicz K, Paris PL, Tao Q, Kowbel D, Lapuk A, Shagin DA, Shagina IA, Gray JW, Cheng JF, de Jong PJ, Pevzner P, Collins C.

Genome Res. 2006 Mar;16(3):394-404. Epub 2006 Feb 3.

30.

Preliminary evaluation of prostate cancer metastatic risk biomarkers.

Paris PL, Weinberg V, Simko J, Andaya A, Albo G, Rubin MA, Carroll PR, Collins C.

Int J Biol Markers. 2005 Jul-Sep;20(3):141-5.

PMID:
16247872
31.

Construction and application of a full-coverage, high-resolution, human chromosome 8q genomic microarray for comparative genomic hybridization.

van Duin M, van Marion R, Watson JE, Paris PL, Lapuk A, Brown N, Oseroff VV, Albertson DG, Pinkel D, de Jong P, Nacheva EP, Dinjens W, van Dekken H, Collins C.

Cytometry A. 2005;63(1):10-9.

32.

An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener's granulomatosis.

Zhou Y, Huang D, Paris PL, Sauter CS, Prock KA, Hoffman GS.

Arthritis Rheum. 2004 Aug;50(8):2645-50.

33.

Molecular analysis of WFDC1/ps20 gene in prostate cancer.

Watson JE, Kamkar S, James K, Kowbel D, Andaya A, Paris PL, Simko J, Carroll P, McAlhany S, Rowley D, Collins C.

Prostate. 2004 Oct 1;61(2):192-9.

PMID:
15305342
34.

Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer.

Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA, Hsi BL, Byrne JA, Pienta KJ, Collins C, Sellers WR, Chinnaiyan AM.

Cancer Res. 2004 Jun 1;64(11):3814-22.

35.

Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors.

Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JE, Volik S, Albertson DG, Pinkel D, Alers JC, van der Kwast TH, Vissers KJ, Schroder FH, Wildhagen MF, Febbo PG, Chinnaiyan AM, Pienta KJ, Carroll PR, Rubin MA, Collins C, van Dekken H.

Hum Mol Genet. 2004 Jul 1;13(13):1303-13. Epub 2004 May 11.

PMID:
15138198
36.

Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer.

Watson JE, Doggett NA, Albertson DG, Andaya A, Chinnaiyan A, van Dekken H, Ginzinger D, Haqq C, James K, Kamkar S, Kowbel D, Pinkel D, Schmitt L, Simko JP, Volik S, Weinberg VK, Paris PL, Collins C.

Oncogene. 2004 Apr 22;23(19):3487-94.

PMID:
15007382
37.

Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.

Cicek MS, Conti DV, Curran A, Neville PJ, Paris PL, Casey G, Witte JS.

Prostate. 2004 Apr 1;59(1):69-76.

PMID:
14991867
38.

Evaluation of genetic patterns in different tumor areas of intermediate-grade prostatic adenocarcinomas by high-resolution genomic array analysis.

van Dekken H, Paris PL, Albertson DG, Alers JC, Andaya A, Kowbel D, van der Kwast TH, Pinkel D, Schröder FH, Vissers KJ, Wildhagen MF, Collins C.

Genes Chromosomes Cancer. 2004 Mar;39(3):249-56.

PMID:
14732926
39.

Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.

Loukola A, Chadha M, Penn SG, Rank D, Conti DV, Thompson D, Cicek M, Love B, Bivolarevic V, Yang Q, Jiang Y, Hanzel DK, Dains K, Paris PL, Casey G, Witte JS.

Eur J Hum Genet. 2004 Apr;12(4):321-32.

40.

CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer.

Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G, Witte JS.

Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):928-32.

41.

High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays.

Paris PL, Albertson DG, Alers JC, Andaya A, Carroll P, Fridlyand J, Jain AN, Kamkar S, Kowbel D, Krijtenburg PJ, Pinkel D, Schröder FH, Vissers KJ, Watson VJ, Wildhagen MF, Collins C, Van Dekken H.

Am J Pathol. 2003 Mar;162(3):763-70.

42.

Prostate cancer aggressiveness locus on chromosome 7q32-q33 identified by linkage and allelic imbalance studies.

Neville PJ, Conti DV, Paris PL, Levin H, Catalona WJ, Suarez BK, Witte JS, Casey G.

Neoplasia. 2002 Sep-Oct;4(5):424-31.

43.

Diffuse large B-cell lymphoma of the stomach: assessment of microsatellite instability, allelic imbalance, and trisomy of chromosomes 3, 12, and 18.

Skacel M, Paris PL, Pettay JD, Tsiftsakis EK, Tubbs RR, Casey G, Hsi ED.

Diagn Mol Pathol. 2002 Jun;11(2):75-82.

PMID:
12045710
44.
45.

Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients.

Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, Casey G, Witte JS.

Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):901-5.

46.

Probing DNA sequences in solution with a monomer-excimer fluorescence color change.

Paris PL, Langenhan JM, Kool ET.

Nucleic Acids Res. 1998 Aug 15;26(16):3789-93.

47.

Experimental Measurement of Aromatic Stacking Affinities in the Context of Duplex DNA.

Guckian KM, Schweitzer BA, Ren RX, Sheils CJ, Paris PL, Tahmassebi DC, Kool ET.

J Am Chem Soc. 1996 Aug 28;118(34):8182-8183. No abstract available.

48.

Naphthalene, Phenanthrene, and Pyrene as DNA Base Analogues: Synthesis, Structure, and Fluorescence in DNA.

Ren RX, Chaudhuri NC, Paris PL, Rumney S, Kool ET.

J Am Chem Soc. 1996 Aug 21;118(33):7671-7678.

Supplemental Content

Loading ...
Support Center